Development of parenteral formulation for a novel angiogenesis inhibitor, CKD-732 through complexation with hydroxypropyl-β-cyclodextrin
- 19 March 2004
- journal article
- research article
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 272 (1-2) , 79-89
- https://doi.org/10.1016/j.ijpharm.2003.11.034
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- Structural and physicochemical characterization of the inclusion complexes of cyclomaltooligosaccharides (cyclodextrins) with melatoninPublished by Elsevier ,2002
- Solubilization of NSC-639829International Journal of Pharmaceutics, 2001
- Pharmaceutical Applications of Cyclodextrins. III. Toxicological Issues and Safety EvaluationJournal of Pharmaceutical Sciences, 1997
- Effect of SBE4-β-CD, a sulfobutyl ether β-cyclodextrin, on the stability and solubility of O6-benzylguanine (NSC-637037) in aqueous solutionsInternational Journal of Pharmaceutics, 1995
- A proton nuclear magnetic resonance study of the inclusion complex of naproxen with β-cyclodextrinInternational Journal of Pharmaceutics, 1994
- Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growthNature, 1990
- High-Field Nuclear Magnetic Resonance Techniques for the Investigation of a β-Cyclodextrin:Indomethacin Inclusion ComplexJournal of Pharmaceutical Sciences, 1990
- An intravenous toxicity study of 2-hydroxypropyl-β-cyclodextrin, a useful drug solubilizer, in rats and monkeys☆International Journal of Pharmaceutics, 1990
- Endothelial proliferation in tumours and normal tissues: Continuous labelling studiesBritish Journal of Cancer, 1984
- Tumor Angiogenesis: Therapeutic ImplicationsNew England Journal of Medicine, 1971